Follicular Lymphoma · line 3 · Axicabtagene ciloleucel (axi-cel) CAR-T for r/r FL — single infusion after lymphodepletion (ZUMA-5)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 3 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-CAR-T-AXICEL-FL |
| ID | IND-FL-3L-AXICEL-CART |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-FL |
| Sources | SRC-ESMO-LYMPHOMA-2025 SRC-NCCN-BCELL-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Aggressive-track 3L+ CAR-T option for r/r FL. Ukraine access constraint dominant: international referral pathway (Israel / Poland / Germany / Spain) + USD 350-500K all-in cost. Liso-cel (TRANSCEND FL-001) is alternative CD19 CAR-T product with lower CRS/ICANS — separate future Indication.
Used By
Algorithms
ALGO-FL-2L- ALGO-FL-2L